Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Wajeeh Khan

UNBELIEVABLE: Regeneron stock just hit a 2 year high heres why - The Untold Story

Regeneron Pharmaceuticals (REGN) shares soared to a fresh two-year high on Oct. 30 after blockbuster inflammation drug Dupixent powered a substantial Q3 earnings beat. Developed in collaboration with Sanofi (SNY), the treatment brought in roughly $6.5 billion in quarterly sales, handily beating the $6.1 billion consensus estimate.

Versus its year-to-date low, Regeneron stock is now trading roughly 50% higher.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.